Company intelligence / Profile preview

Novomics

Ownership: Private
Employees: ~27
Development stage: Commercial

Overview

Novomics has developed and clinically validated the nProfiler® series of molecular diagnostic assays for various cancers—most notably gastric—and an AI-powered digital pathology solution. Multiple retrospective and prospective clinical studies have been completed or are ongoing to validate these tools' effectiveness in predicting prognosis and chemotherapy response in resectable gastric cancer patients.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Diagnostic assay (Molecular diagnostics)AI-assisted digital pathologyDevice (for auto sampling system)COVID‑19 detection kit
Industry: Molecular Diagnostics

Partnerships

Collaborations with pharmaceutical companies and hospitals for clinical research and product development

Beyond the preview

Go deeper on Novomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novomics.

Explore the full profile